SI-BONE to Host Financial Results Conference Call
SI-BONE, Inc. (Nasdaq: SIBN), a leading medical device company focused on addressing sacropelvic disorders, is set to announce its financial results for the second quarter of 2025. This important update will take place after market closure on a specified date. Following the results announcement, management will conduct a conference call starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, allowing investors to gain further insights.
How to Access the Conference Call
Investors can listen to the conference call by registering through a provided link. Additionally, a live audio webcast will be accessible in the “Investors” section of the company’s website. There, interested parties can find the archived version, which will remain available for at least 90 days, ensuring that those who cannot attend the live session still have the opportunity to catch up on the information shared.
About SI-BONE, Inc.
SI-BONE has made a name for itself as a pioneer in the development of surgical technologies aimed at treating sacropelvic disorders. Their journey began in 2009 when they introduced the iFuse Implant System, an innovative solution for minimally invasive SI joint surgery. The company has empowered over 4,500 physicians who have collectively completed more than 125,000 procedures, highlighting the trust and reliance within the medical community.
Innovative Clinical Evidence
To back its advancements, SI-BONE boasts an impressive array of clinical research, encompassing more than 175 peer-reviewed publications, which include rigorous randomized controlled trials. These studies are critical in validating the efficacy of their products, demonstrating their commitment to enhancing patient care through evidence-based practices.
Expanding Horizons in Medical Technology
Building on their success in minimally invasive SI joint fusion, SI-BONE has diversified its offerings. They are now introducing novel solutions aimed at adjacent markets, which include adult deformity treatments and pelvic trauma interventions. Their innovative approach ensures that they remain at the forefront of medical device technology, continuously exploring new ways to improve patient outcomes.
Commitment to Safety and Efficacy
The dedication to safety and efficacy is evident in every product they develop. Each solution is meticulously designed to ensure it meets the rigorous standards required for surgical interventions. As a result, healthcare providers can confidently use SI-BONE products to address complex sacropelvic conditions.
Connect with SI-BONE
For comprehensive information about SI-BONE’s products, including the risks and benefits associated with their use, you can visit their official website. Here, a wealth of resources is available for both medical professionals and patients, promoting informed decisions regarding treatment options.
Investor Relations
Investors looking to learn more about the company can reach out directly to Saqib Iqbal. Their investment inquiries are welcome, and the company is committed to maintaining transparent communication with its stakeholders.
Frequently Asked Questions
What is the date of SI-BONE's upcoming financial results announcement?
SI-BONE will announce its financial results after market close on a specified date in August.
How can I access the conference call?
You can listen to the conference call by registering through the link provided in the announcement.
Is there a replay available for the conference call?
Yes, the audio webcast will be archived and available for at least 90 days after the call.
What products does SI-BONE offer?
SI-BONE specializes in surgical solutions for sacropelvic disorders, including the iFuse Implant System.
How can I get in touch with SI-BONE's investor relations?
You can contact Saqib Iqbal for any investment-related inquiries.
